These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 12132563

  • 21. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis.
    Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN.
    Clin Ther; 2001 Jan; 23(1):97-107. PubMed ID: 11219483
    [Abstract] [Full Text] [Related]

  • 22. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective.
    Lorenz J, Thate-Waschke IM, Mast O, Kubin R, Rychlik R, Pfeil T, Daniel D, Tillotson GS.
    J Int Med Res; 2001 Jan; 29(2):74-86. PubMed ID: 11393351
    [Abstract] [Full Text] [Related]

  • 23. Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis.
    Langan CE, Zuck P, Vogel F, McIvor A, Peirzchala W, Smakal M, Staley H, Marr C.
    J Antimicrob Chemother; 1999 Oct; 44(4):515-23. PubMed ID: 10588313
    [Abstract] [Full Text] [Related]

  • 24. Gemifloxacin.
    Lowe MN, Lamb HM.
    Drugs; 2000 May; 59(5):1137-47; discussion 1148. PubMed ID: 10852645
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin.
    Hammerschlag MR.
    J Antimicrob Chemother; 2001 Nov; 48(5):735. PubMed ID: 11679567
    [No Abstract] [Full Text] [Related]

  • 26. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
    Chodosh S, Schreurs A, Siami G, Barkman HW, Anzueto A, Shan M, Moesker H, Stack T, Kowalsky S.
    Clin Infect Dis; 1998 Oct; 27(4):730-8. PubMed ID: 9798025
    [Abstract] [Full Text] [Related]

  • 27. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA, Mathew CP, Warner JH, Heyd A, Church D.
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [Abstract] [Full Text] [Related]

  • 28. Comparison of chest X-ray findings and other parameters in acute exacerbation of chronic bronchitis in Japan and the West.
    Watanabe A, Kohno S, Niki Y, Saito A.
    J Infect Chemother; 2001 Mar; 7(1):37-44. PubMed ID: 11406755
    [Abstract] [Full Text] [Related]

  • 29. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Mar; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
    Najib MM, Stein GE, Goss TF.
    Pharmacotherapy; 2000 Apr; 20(4):461-9. PubMed ID: 10772376
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Clarithromycin Leads to Long-Term Survival and Cost Benefit in Ventilator-Associated Pneumonia and Sepsis.
    Tsaganos T, Raftogiannis M, Pratikaki M, Christodoulou S, Kotanidou A, Papadomichelakis E, Armaganidis A, Routsi C, Giamarellos-Bourboulis EJ.
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3640-6. PubMed ID: 27044546
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Acute exacerbation of chronic bronchitis: disease-specific issues that influence the cost-effectiveness of antimicrobial therapy.
    Saint S, Flaherty KR, Abrahamse P, Martinez FJ, Fendrick AM.
    Clin Ther; 2001 Mar; 23(3):499-512. PubMed ID: 11318083
    [Abstract] [Full Text] [Related]

  • 40. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
    Llor C, Naberan K, Cots JM, Molina J, Miravitlles M.
    Int J Clin Pract; 2004 Oct; 58(10):937-44. PubMed ID: 15587773
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.